In Vitro Activities of Cefiderocol, Ceftazidime–Avibactam, Meropenem–Vaborbactam, Imipenem–Relebactam and Eravacycline Against Carbapenem-Resistant Klebsiella pneumoniae
AIM/BACKGROUND: Carbapenem-resistant Klebsiella pneumoniae (CRKP) infections are a significant global threat due to the limited treatment options. In this study, in vitro activities of novel antimicrobial agents were investigated against CRKP strains. METHODS: Eighty-five CRKP clinical isolates were...
Saved in:
Main Authors: | FATMA SENA TÜRKDOĞAN, Betigul Ongen |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-12-01
|
Series: | Journal of Global Antimicrobial Resistance |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2213716524002741 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparison of meropenem-vaborbactam with ceftazidime-avibactam in the treatment of carbapenem-resistant Enterobacterales infections
by: Luca Mezzadri, et al.
Published: (2024-12-01) -
Real-World Experience of Imipenem–Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study)
by: Isabel Machuca, et al.
Published: (2024-11-01) -
Cefiderocol in the Successful Treatment of Complicated Hospital-Acquired K. pneumoniae NDM, OXA48 Intraabdominal Infection
by: Tarski I, et al.
Published: (2024-11-01) -
An Assessment Of Cefiderocol's Synergistic Effects With Eravacycline, Colistin, Meropenem, Levofloxacin, Ceftazidime/Avibactam, And Tobramycin Against Carbapenem-Resistant Pseudomonas Aeruginosa
by: Bekir Özer, et al.
Published: (2024-12-01) -
National Cohort of Compassionate Use of Meropenem–Vaborbactam: No Benefit over Meropenem for <i>Pseudomonas aeruginosa</i>
by: Aurélien Dinh, et al.
Published: (2024-12-01)